New Conferences
(7 records)
Page 1 of 1
Sort by :

   

Sep 20, 2017
Oct 10, 2017

STRATEGIES TO MOVE US PAST CHOP IN PERIPHERAL T-CELL LYMPHOMA

  • Review of the different PTCL subtypes (angioimmunoblastic, hepatosplenic, anaplastic ALK-1 (-) or (+), etc..) with clinical presentation, prognosis and treatments
  • Review of PTCL NOS with focus on treatments. Are CHOP or CHOP-like regimens still the standard of care?
  • Future Horizons on treatment of PTCL and what are the research developments
Dr. Steven Horwitz
Treatment of Peripheral T-cell Lymphoma, CHOP, CHOP-like, research developments
Sep 20, 2017
Oct 10, 2017

AGING AND ANTI-AGING PRODUCTS

Aging is a focus of extensive research. While there is a great deal of unsubstantiated hype when it comes to various supplements and regimens, there is also serious research into calorie restriction, rapamycin, sirtuins and telomerase.
Joe Schwarcz PhD
Resveratrol, sirtuins, calorie restriction, rapamycin, telomerase, antioxidants, human growth hormone, cryonics, Souvenaid, Steinach, Brown-Sequard
Sep 14, 2017
Oct 10, 2017

TRANS HEALTH 101: APPROACH AND SENSITIVITY

Brief overview of needs, barriers and best practices that health care providers should understand in order to improve access and quality of trans care. Participants will have an increased understanding of gender diversity, and of common barriers faced by trans and gender non-conforming youth accessing health care. Participants will be able to list three simple measures that they might integrate into their practice in order to increase the gender-affirming nature of their environment.
Mr. Tynan Jarrett
Trans, transgender, cisgender, barriers, access, health care
Sep 14, 2017
Oct 10, 2017

TRANS HEALTH 101: MEDICAL CONSIDERATIONS

This presentation will provide standards of care and resources for health care professionals to incorporate the appropriate medical management and health supervision for transgender individuals into their practice. At the conclusion of this activity, participants will be able to:
  • Identify the phases of gender transition
  • Cite and use medical protocols for prescribing blockers and cross sex hormones
  • Perform routine health maintenance screening for transgender individuals
Dr. Annie Sbrocchi & Dr. Andrew Bui Nguyen
transgender, blockers, cross hormones, health supervision, WPATH, dysphoria, estrogen, testosterone, informed consent, tanner staging
Jun 14, 2017
Jul 31, 2017

QUALITY IMPROVEMENT (QI) AND PATIENT SAFETY IN ONCOLOGY

  • Understand the principles of Quality Improvement initiatives and how to start implementing projects in their own departments
  • Recognize factors leading to errors in practice and how to establish a positive safety culture in their own department
  • Design systems to evaluate practice and safety by using techniques such as systems theory and process control
Dr. Todd Pawlicki, PHD, FAAPM Professor and Vice-Chair of Medical Physics Division Director Department of Radiation Medicine and Applied Sciences University of California, San Diego
Quality Improvement, implementing projects, safety culture, Design systems
May 24, 2017
Jul 31, 2017

WHAT IS TIMELY TREATMENT INITIATION IN FOLLICULAR LYMPHOMA AND WHY IT MATTERS?!

  • Describe current initial treatment paradigms and associated outcomes for follicular lymphoma
  • Review current evidence regarding the prognostic factors/biomarkers in support of timely treatment initiation
  • Determine the key aspects of the clinician-patient communications related to treatment and its initiation
PIER LUIGI ZINZANI, MD, PHD Professor of Hematology Institute of Hematology "L. e A. Seràgnoli" University of Bologna Bologna, Italy
initial treatment, follicular lymphoma, prognostic factors/biomarkers, clinician-patient communications
May 18, 2017
Jul 31, 2017

INTEGRATED DIAGNOSIS OF LUNG CANCER - HOW CAN WE OBTAIN ALL THE USEFUL DIAGNOSTIC INFORMATION WITH A SMALL BIOPSY?

  • To understand the importance of molecular testing in the diagnosis and management of NSCLC
  • To be familiarized with new technologies that allow for more comprehensive molecular diagnoses
  • To appreciate how quantity of tissue impacts the molecular testing that can be done, and the trade-offs with minimizing procedural risks to patients
  • To discuss ways that ensure maximal diagnostic value is obtained when limited tissue is available
DR. MING-SOUND TSAO, FRCPC, MD
molecular testing, diagnosis and management of NSCLC new technologies, minimizing procedural risks to patients, discuss ways that ensure maximal diagnostic value

1

 

From Montreal, QC, Canada
Copyright © 2002-2017 Continuing Professional Development (CPD) Office,
Faculty of Medicine, McGill University